Agilvax News

Subscribe to our newsletter to stay informed about important Agilvax news.




Agilvax Appoints Joseph Patti, Ph.D. as Executive Chairman

Albuquerque, NM

November 13, 2018

Agilvax, Inc., a biotechnology company developing targeted antibody-based therapeutics for the treatment of various types of cancers announced today that Joseph Patti, Ph.D., will join its Board of Directors as Executive Chairman.

Read More

Agilvax Awarded $2.3 Million SBIR Fast Track Grant to Advance the Development of AX09 for Triple Negative Breast Cancer

Albuquerque, NM

August 7, 2018

Agilvax, Inc., a biotechnology company developing a novel cancer immunotherapy for the treatment of triple negative breast cancer (TNBC), announced today the receipt of a Fast Track Small Business Innovation Research (SBIR) grant from the National Cancer Institute (NCI).

Read More

Agilvax Closes A1 Financing to Expand Pre-IND Studies for AX09 In Triple Negative Breast Cancer

Albuquerque, NM

May 15, 2018

Agilvax, Inc., a biotechnology company that develops targeted cancer immunotherapies and vaccines, has completed a Series A1 financing, which complements the Series A round from 2014. Both Series A and A1 were led by Hunt Holdings with a co-investment by Sun Mountain Capital. The funds will be used to expand the pre-IND studies for its lead program AX09 in triple negative breast cancer (TNBC).

Read More

Agilvax Establishes Operations at JLABS @ TMC in Houston

Albuquerque, NM

May 01, 2018

Agilvax, Inc., a biotechnology company developing novel cancer immunotherapies and vaccines, announced today that it is now a resident company at Johnson & Johnson Innovation, JLABS (JLABS @ TMC) at the renowned Texas Medical Center—the world’s largest cancer center—located in Houston, TX .

Read More

Agilvax to Attend J.P. Morgan Healthcare Conference, Biotech Showcase™ 2018 & RESI San Francisco 2018

Albuquerque, NM

January 04, 2018

Agilvax Inc., a biotechnology company that develops targeted cancer immunotherapies and vaccines, announced today that its management team Dr. Federica Pericle (President & CEO) and Les Stewart (COO) will be attending J.P. Morgan Healthcare Conference, Biotech Showcase™ 2018 and RESI San Francisco 2018.

Read More

New Scientific Publication Supports Agilvax’s Novel Immunotherapy Development for Metastatic Breast Cancer

Albuquerque, NM

December 05, 2017

Agilvax, Inc. announced a significant milestone for its immunotherapy, AX09, for the treatment of triple negative breast cancer (TNBC).

Read More

Agilvax to Attend 10th Annual BioPharm America & RESI Boston Conferences

Albuquerque, NM

September 22, 2017

Federica Pericle, President & CEO, will be attending the 10th Annual BioPharm America Conference in Boston, MA, September 26-27, 2017.

Read More

Agilvax Selected for Springboard Health Innovation Hub 2017

Albuquerque, NM

April 06, 2017

Federica Pericle, PhD, MBA President and CEO of Agilvax was accepted into the 2017 Pharma class of the Springboard Health Innovation Hub.

Read More

Agilvax to Showcase Data During AACR 2017 Annual Meeting in Washington, DC

Albuquerque, NM

March 31, 2017

Agilvax, Inc., announced today that Dr. John O’Rourke, Director of Oncology, will be presenting a poster, AX09: An Immunotherapy Candidate Targeting the Breast Cancer Stem Cell Protein xCT, at the American Association for Cancer Research (AACR) Annual Meeting to be held in Washington, DC, April 1-5, 2017.

Read More

Agilvax Awarded Subcontract by Leidos to Develop a Malaria Vaccine

Albuquerque, NM

November 17, 2016

Agilvax, Inc., today announced that it has been awarded a subcontract from Leidos valued at approximately $400,000 for the screening and development of a potential epitope-based malaria vaccine candidate.

Read More

Faith Charles Joins Agilvax’s Board Of Directors

Albuquerque, NM

September 14, 2016

Agilvax, Inc. today announced that Faith L. Charles, partner in Thompson Hine‘s Corporate Transactions & Securities practice group and chair of the firm’s Life Sciences group, has been elected to Agilvax’s board of directors, effective September 13, 2016.

Read More

Agilvax Receives New Patent for Its Cost-Effective Broadly Protective HPV Vaccine Candidate

Albuquerque, NM

September 06th, 2016

Agilvax, Inc. a leader in the discovery and development of vaccines and cancer immunotherapies is pleased to announce the Notice of Allowance by the U.S. Patent and Trademark office on August 26, 2016 of a new patent related to the company’s human papillomavirus (HPV) vaccine candidate.

Read More

Agilvax Appoints Dr. Brad Vale Former Head of Johnson & Johnson Development Corporation (JJDC) to its Board Of Directors

Albuquerque, NM

July 20th, 2016

Agilvax, Inc. today announced it has appointed Brad Vale, PhD, DVM to its Board of Directors. Dr. Vale is an expert corporate executive in the biotechnology, pharmaceutical and medical device investing arena. His appointment was effective July 20th 2016.

Read More

Agilvax Receives SBIR Grant to Advance Development of A VLP Based RSV Vaccine

Albuquerque, NM

July 6th, 2016

National Institute of Allergy and Infectious Diseases (NIAID) has awarded Agilvax a one-year, $286,000 grant under the Small Business Innovation Research (SBIR) program entitled “Development of a VLP-based RSV vaccine targeting pre-fusion F protein.”

Read More

Agilvax Receives Notice of Allowance for U.S. and European Patents Covering its Vaccine and Cancer Immunotherapy Discovery and Development Platform Technology

Albuquerque, NM

February 29th, 2016

Agilvax, Inc. is pleased to announce that it has recently received a Notice of Allowance in United States Patent Application serial number 13/520,057 and an Intention to Grant in European Patent Application 10841780.9 entitled, “Plasmids and Methods for Peptide Display and Affinity-Selection on Virus-Like Particles of RNA Bacteriophages”.

Read More

Agilvax to Attend The 34th Annual J.P. Morgan Healthcare Conference and the 8th Annual Biotech Showcase Conference

Albuquerque, NM

January 8, 2016

Agilvax Inc., announced today that Dr. Federica Pericle, President & CEO, and Michael Perrine, Director of Business Development will be representing Agilvax during the 34th Annual J.P. Morgan Healthcare Conference and the 8th Annual Biotech Showcase Conference in San Francisco, CA January 11-14, 2016.

Read More

Agilvax announces Strategic Collaboration with Integrated BioTherapeutics to Develop a Novel Pan-Ebola Vaccine

Albuquerque, NM

July 20, 2015

Agilvax, Inc. today announced a collaboration with Integrated BioTherapeutics (IBT), a leader in filovirus and other emerging infectious disease research, to develop novel vaccines against filoviruses such as Ebola and Marburg.

Read More

Agilvax to Collaborate With Sandia National Laboratories & NMSBA To Develop Vaccines And Immunotherapies That Lack Cold-chain Requirements

Albuquerque, NM

May 12, 2015

Agilvax, Inc. announced an agreement with Sandia National Laboratories to optimize the long-term stability and efficacy of the Company’s products.

Read More

Agilvax To Present At The 2015 Annual Conference On Vaccine Research and Attend The 7th Annual ChinaBio Partnering Forum

Albuquerque, NM

April 8, 2015

Agilvax Inc., a biotechnology company that develops vaccines and immunotherapies to combat infectious diseases and cancer, announced today that Dr. Mitchell Tyler, Director of Research & Development, will be presenting a poster at the 2015 Annual Conference on Vaccine Research in Bethesda, MD April 13-15, 2015.

Read More

Agilvax to Attend 12th Annual Bio Asia International Conference

Albuquerque, NM

March 18, 2015

Agilvax Inc., a biotechnology company that develops vaccines and immunotherapies to combat infectious diseases and cancer, announced today that that President & CEO, Federica Pericle, will attend the 12th Annual Bio Asia International Conference in Tokyo, Japan, March 24-25, 2015.

Read More

Agilvax Announces Strategic Collaboration with Humabs BioMed SA to Develop Targeted Vaccines and Immunotherapies

Albuquerque, NM

February 17, 2015

Agilvax, Inc. today announced a collaboration with Switzerland based Humabs BioMed that will contribute to the rapid advancement of Agilvax’s ever expanding vaccine and immunotherapy pipeline.

Read More

Agilvax Is Advancing Clinical Production of its Lead Vaccine Against Human Papillomavirus (HPV)

Albuquerque, NM

February 03, 2015

Albuquerque, NM (February 03, 2015) - Agilvax, Inc. announced an agreement with the Division of Microbiology and Infectious Diseases (DMID) of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH) to expedite the clinical development of Agilvax’s virus-like-particle (VLP) vaccine targeting human papillomavirus (HPV).

Read More

Agilvax To Attend Biotech Showcase™ 2015

Albuquerque, NM

January 5, 2015

Agilvax Inc. announced today that Michael Perrine, MS, MBA, Director of Business Development will be representing the company at the 7th Annual Biotech Showcase™ in San Francisco January 12-14, 2015. Agilvax welcomes the opportunity to discuss its first-in-class immunotherapy and vaccine discovery and development platform.

Read More

Agilvax President and CEO, Federica Pericle, tied for first place at the RMVCA2014: ABQ Pitch Unplugged

Albuquerque, NM

August 28, 2014

On Thursday August 28, 2014 Agilvax President and CEO, Federica Pericle, tied for first place at the Rocky Mountain Venture Capital Association 2014 ABQ Pitch Unplugged event at Albuquerque’s Marble Brewery.

Read More

Agilvax Lands $2 Million In Series A Funding

By Dan Mayfield / Reporter-Albuquerque Business First

July 31, 2014

Albuquerque biotech firm Agilvax has landed $2 million in Series A funding to develop its virus-like particle technology.

Read More

UNM Tech Speeding Up Vaccine Development

By Kevin Robinson-Avila / Journal Staff Writer

June 23, 2014

An Albuquerque startup may soon bring the world’s first vaccines for malaria and dengue to market with break through technology from the University of New Mexico.

Read More